Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard
Joel Simrén(University of Gothenburg), Nicholas J. Ashton(King's College London), Kaj Blennow(Sahlgrenska University Hospital), Niklas Mattsson(Malmö University), Antoine Leuzy(Banner Sun Health Research Institute), Oskar Hansson(Eli Lilly (United States)), Bruno Vellas(Centre Hospitalier Universitaire de Toulouse), Abdul Hye(King's College London), Iwona Kłoszewska(Medical University of Lodz), Dag Aarsland(King's College London), Thomas K. Karikari(University of Pittsburgh), Magda Tsolaki(Aristotle University of Thessaloniki), Michael Schöll(Wallenberg Wood Science Center), Henrik Zetterberg(University of Wisconsin–Madison), Hilkka Soininen(University of Eastern Finland), Simon Lovestone(Royal Buckinghamshire Hospital), Eric Westman(Wellcome Centre for Human Neuroimaging), Patrizia Mecocci(University of Perugia)
Cited by 0
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k